EUVIMEDEUVIMED entdecken
Crossref

Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC

Mary Beth Nierengarten

Cancer · 2024

DOI: 10.1002/cncr.35529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Mary Beth Nierengarten. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 2 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, durvalumab remains inaccessible to many patients for whom it is indicated as a standard of care after chemoradiation. In addition, a study assesses a fixed‐duration combination regimen of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia, and multitargeted therapy is safe and leads to durable remission of diffuse large B‐cell lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisCarcinoma, Non-Small-Cell LungAntibodies, MonoclonalLung NeoplasmsChemoradiotherapyHumansNeoplasm StagingAntineoplastic Agents, ImmunologicalStandard of Care

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Zitieren

APA

Nierengarten, M. B. (2024). Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC. Cancer. https://doi.org/10.1002/cncr.35529

Vancouver

Nierengarten MB. Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC. Cancer. 2024. doi:10.1002/cncr.35529

BibTeX
@article{Nierengarten2024,
  author = {Nierengarten, Mary Beth},
  title = {Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35529}
}
Kostenlos starten →